SELECT PUBLICATIONS

Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now? Eur J Cancer 2005;41(12):1667-77. Abstract

Bertelli G. Sequencing of aromatase inhibitors. Br J Cancer 2005;93(Suppl 1):6-9. Abstract

Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Delozier T et al. Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): Ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group. San Antonio Breast Cancer Symposium 2005;Abstract 14.

Duffy S et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21(2):545-53. Abstract

Duffy SR, Distler W, on behalf of the ATAC Trialists’ group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. San Antonio Breast Cancer Symposium 2005;Abstract 2056.

Fisher B et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88(21):1529-42. Abstract

Gltick S. Changing the gold standard in adjuvant therapy for breast cancer: From tamoxifen to aromatase inhibition. Biomed Pharmacother 2005;59(Suppl 2):321-2. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005a;97(17):1262-71. Abstract

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005b;Abstract 16.

Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69(1):1-9. Abstract

Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 2005;93(2-5):237-47. Abstract

Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. San Antonio Breast Cancer Symposium 2005;Abstract 17.

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005a;366(9484):455- 62. Abstract

Jakesz R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. San Antonio Breast Cancer Symposium 2005b;Abstract 13.

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005;131(8):487-94. Abstract

Mann BS et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 2005;11(16):5671-7. Abstract